These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 33717170)

  • 1. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.
    McCachren SS; Dhodapkar KM; Dhodapkar MV
    Front Immunol; 2021; 12():632564. PubMed ID: 33717170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
    Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass Cytometry Discovers Two Discrete Subsets of CD39
    Marsh-Wakefield F; Kruzins A; McGuire HM; Yang S; Bryant C; Fazekas de St Groth B; Nassif N; Byrne SN; Gibson J; Brown C; Larsen S; McCulloch D; Boyle R; Clark G; Joshua D; Ho PJ; Vuckovic S
    Front Immunol; 2019; 10():1596. PubMed ID: 31428081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGUS to myeloma: a mysterious gammopathy of underexplored significance.
    Dhodapkar MV
    Blood; 2016 Dec; 128(23):2599-2606. PubMed ID: 27737890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
    Seth S; Zanwar S; Vu L; Kapoor P
    Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV
    Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
    Gámez B; Edwards CM
    Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.
    McShane CM; Murray LJ; Landgren O; O'Rorke MA; Korde N; Kunzmann AT; Ismail MR; Anderson LA
    Cancer Epidemiol Biomarkers Prev; 2014 Feb; 23(2):332-42. PubMed ID: 24451437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
    Zavidij O; Haradhvala NJ; Mouhieddine TH; Sklavenitis-Pistofidis R; Cai S; Reidy M; Rahmat M; Flaifel A; Ferland B; Su NK; Agius MP; Park J; Manier S; Bustoros M; Huynh D; Capelletti M; Berrios B; Liu CJ; He MX; Braggio E; Fonseca R; Maruvka YE; Guerriero JL; Goldman M; Van Allen EM; McCarroll SA; Azzi J; Getz G; Ghobrial IM
    Nat Cancer; 2020 May; 1(5):493-506. PubMed ID: 33409501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.
    Barwick BG; Gupta VA; Vertino PM; Boise LH
    Front Immunol; 2019; 10():1121. PubMed ID: 31231360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
    Allegra A; Innao V; Allegra AG; Pugliese M; Di Salvo E; Ventura-Spagnolo E; Musolino C; Gangemi S
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
    Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
    Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
    Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
    Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.